Navigation Links
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
Date:5/8/2009

million, or $0.76 per share, for the nine months ended March 31, 2008.

Cash, cash equivalents and investments were $28.8 million at March 31, 2009. The cash and total investments balance included cash, cash equivalents and short-term investments of $21.6 million and long-term auction-rate securities carried at an estimated value of $7.2 million and classified as long-term investments. Total liabilities, excluding deferred revenue of $14.7 million and a warrant liability of $0.2 million, were $6.4 million at March 31, 2009.

"During the third quarter of fiscal 2009, we wound-down most of our operations and significantly reduced expenses. We also initiated a process to identify and evaluate alternatives for the Company's future. Our board's stated mandate in looking at these strategic alternatives is to maximize the value of our cash and other assets for the benefit of all our shareholders, and to proceed expeditiously in the process," stated William Fletcher, acting Chief Executive Officer.

Assuming accrued costs associated with the Viprinex program are fully paid off by June 30, 2009 as currently estimated, the Company expects to end its fiscal year with approximately $23 million in cash, short-term and long-term investments.

-Tables to follow -

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials as a potential new drug to treat acute ischemic stroke. NTI has more recently chosen not to extend its early-stage research programs for Huntington's and Alzheimer's diseases. NTI has rights to receive payments from an approved drug for Alzheimer's disease and an invest
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
2. Neurobiological Technologies Reports Second Quarter Financial Results
3. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. Neurobiological Technologies Reports Going Concern Qualification
8. Steven H. Kane Appointed as President and Chief Executive Officer of Patient Safety Technologies, Inc.
9. Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009
10. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
11. Greenway Medical Technologies PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... mutation that causes a rare premature aging disease could ... rapid, unstoppable cell division that makes cancer so deadly. ... the U-M Health System recently discovered a protein mutation ... precious hematopoietic stem cells can,t regenerate and make new ... to cancer and bone marrow failure. , But ...
(Date:9/30/2014)... FDA-approved injectable dermal fillers (i.e. hyaluronic ... in several procedures that are performed to restore ... primarily used for wrinkle treatment of the skin, ... are being used as popular treatments in nonsurgical ... the hands. (1) (2) Dr. Cynthia Elliott of ...
(Date:9/30/2014)... Mirada, CA (PRWEB) September 30, 2014 ... Cortes is now performing advanced foot and ankle reconstruction ... a board-certified orthopedic surgeon, Dr. Cortés specializes in the ... and ankle injuries . She is also trained to ... with their orthopedic needs. Dr. Cortés is also fluent ...
(Date:9/30/2014)... September 30, 2014 To mark National ... Board of Living with a Disability magazine ... on hematological disorders as disabling conditions. , ... than a diagnosis to establish a disability related to ... myelofibrosis, hereditary telangiectasia, coagulation defects, polycythemia vera, and aplastic ...
(Date:9/30/2014)... Jiwa Law Corporation, a personal injury law ... now be offering free consultation for personal injury claims of ... firm for the first time to meet the Vancouver ICBC ... opportunity to understand what their rights are. The experts at ... to explain to them what the law firm can do ...
Breaking Medicine News(10 mins):Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 3Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 4Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 3Health News:Living with a Disability Magazine Marks National Sickle Cell Health Month with New Article on Hematological Disorders 2Health News:Living with a Disability Magazine Marks National Sickle Cell Health Month with New Article on Hematological Disorders 3Health News:Jiwa Law Corporation Now Offers Personal Injury Consultation Without Any Charge 2
... Reporter , THURSDAY, March 15 (HealthDay News) -- ... or depressed, their children are more likely to develop ... What,s more, the worse the parents scored on ... to develop the problems. "The psychological well-being ...
... (March 16, 2012) An international team of researchers from ... Center in Tampa, Fla., have found that the oral BRAF ... trial offered a high rate of response in patients with ... More than 50 percent of the patients in the trial ...
... biotechnological and chemical methods will facilitate efficient production of ... Academy of Finland Centre of Excellence (CoE) in White ... and development of microbial cells, or cell factories, for ... These compounds can be used, for example, for manufacturing ...
... FRIDAY, March 16 (HealthDay News) -- Being unable to ... deadly outcome for older people, new research reveals. ... 52 and older, who completed a test of functional ... to understand health-related information. Specifically, the test assessed a ...
... the risk of death in patients who have a ... depressed patients were 1.5 times more likely to have ... age, gender, clinical characteristics, anxiety and the distressed (Type ... 12th Annual Spring Meeting on Cardiovascular Nursing , ...
... , THURSDAY, March 15 (HealthDay News) -- Politicians may want ... for votes, because people appear to prefer candidates with deep ... men and women who listened to recordings of high- and ... this November." Both the male and female participants "elected" ...
Cached Medicine News:Health News:Stressed Parents May Affect Preemie Behavior Later 2Health News:Stressed Parents May Affect Preemie Behavior Later 3Health News:Response rate high for some patients with metastatic melanoma treated with vemurafenib 2Health News:Novel plastics and textiles from waste with the use of microbes 2Health News:Poor Reading Skills Might Be Fatal for Older Folks 2Health News:Depression increases death risk in coronary stent patients 2
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... allows Kessler Foundation and New Jersey Health Foundation ... education and patient care programs has been announced ... executive officer of Kessler Foundation and James ... Foundation. "The experience of New Jersey ...
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional ... towels and tissue for a wide range of ... of its product lines in healthcare, including hospitals, ... Georgia-Pacific Professional is introducing its healthcare products and ... Professional understands the importance of infection control in ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
... In addition to three conventional measurement modes ... also incorporates a new axial length measuring ... by calculating sonic velocity for conversion at ... length by calculating each tissues sonic velocity ...
... first very high frequency digital ultrasound eye ... provides microscopic resolution images and precision measurement ... of the human eye. Artemis is a ... In use, the patient leans forward placing ...
... 1000 is the most advanced ophthalmic ultrasound ... operates with a single Macintosh desktop or ... a streamlined internal probe rotator. Every aspect ... The UltraFast 12 MHz B-probe operates on ...
... a combination A-scan and B-scan system, providing ... incorporates a high frequency, low noise probe ... capture immediately upon application of the probe ... the axial length of both eyes differ ...
Medicine Products: